Press Room

Latest

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2006

2005

2004

2003

2002

2001


News - 2013

New US USCOM Distribution Agreement

November 12th, 2013

Uscom Limited today announced the appointment of US distributor MedSource-SW (MedSource) as distributor for the USCOM 1A cardiac monitor in the Southern USA, MedSource have signed a 3 year distribution contract with Uscom Limited. MedSource is a Dallas based medical products distributor specializing in capital sales into the states of Texas, Oklahoma, Louisiana, Arkansas, Missouri, Kansas with good connections into ICU, ED and Paediatrics departments.

Executive Chairman of Uscom, Rob Phillips said, “We are very focused on building sales and distribution and the appointment of MedSource is part of the re-invigoration of the US USCOM market for us. We are looking forward to Scott Peterson and his team taking the USCOM technology into the hospitals of the Southern United States.”

Uscom Limited is currently developing distribution and sales partnerships to accelerate global revenue growth across its two practice changing products, the USCOM 1A cardiac output monitor and the Uscom BP+ central blood pressure monitor. The appointment of MedSource by Uscom is in addition to the execution of a 5 year, $6.6m distribution deal into China and the appointment of a UK based global sales and marketing manager that were recently announced by the Company.

Uscom signs 5 year $7m China sales deal

October 15th, 2013

Uscom Limited today announced completion of an agreement with Naqu Area Pioneer Pharma Co Ltd, Shanghai, a wholly owned subsidiary of China Pioneer Pharma Holdings Limited, to distribute Uscom devices in China. The agreement involves a commitment by China Pioneer to minimum purchases worth approximately $6.6m over 5 years, with target purchases of $8.3m. Distribution will commence on completion of China Food and Drug Administration (CFDA) approval expected in 2014.

China Pioneer Pharma Holdings Limited is a large Shanghai based Chinese medical distribution Company specialising in pharmaceuticals and medical devices, with estimated annual revenue in 2013 of 1.5b RMB ($260m AUD). China Pioneer has approximately 230 in house sales personnel, and is further supported by approximately 1000 third party partners, selling into 20,000 Hospitals and 50,000 drug stores. Pioneer was founded in 1996 by Paul Li (Li Xin Zhou).

President of Pioneer Pharma, Paul Li said, “Uscom has a focus on premium cardiovascular medical devices developed to improve clinical care for widespread application, and this is very much aligned with the philosophy of Pioneer. The Uscom products will be important for our on going growth, and we look forward to working with the Uscom team to deliver premium, cost effective technologies to the Chinese market and rapidly grow Pioneer.”

Executive Chairman of Uscom, Rob Phillips said, “Pioneer Pharma brings Uscom great sales access to the increasingly sophisticated and rapidly growing Chinese medical device market. This commitment to a long-term partnership by Pioneer provides Uscom with a platform on which to introduce new and innovative medical products into China, and having an internationally respected partner is vital for success in China. We have spent many years learning about the Chinese market and building good relationships in China, and we look forward to working with China Pioneer to increase delivery of current and new Uscom devices into China. This is another major step in our commitment to restructuring global distribution and sales and further drives us toward profitability.”

China has a population of 1.35b, and has more than 22,000 hospitals, more than 5.1m hospital beds, and more than 8.6m health care staff. China spends approximately 2.5tr RMB on health care or about 5.5% of GDP, and plans to increase this to 7% by 2020 to become the second largest health care market in the world.

References: WHO, China Statistics Bureau, Ministry of Health of the People’s Republic of China, Ministry of Human Resources and Social Security of the People’s Republic of China, Bank of China.

New Global Sales Manager Appointed

September 24th, 2013

Uscom Limited has announced the appointment of Mr Steve Haken as a UK based global sales manager. Mr Haken will over-see global sales and distribution for Uscom Limited for both the USCOM and BP+ products.

Mr Haken will immediately act to secure the establishment of a new global distribution for the Uscom BP+ suprasystolic central blood pressure device. Mr Haken will also seek new USCOM sales channels and actively motivate and support current USCOM distribution to achieve optimal worldwide sales targets.

Executive Chairman of Uscom, Rob Phillips said, “Uscom’s focus is sales and revenue, and Steven’s appointment is to optimize global sales and distribution for the two breakthrough Uscom technologies. The USCOM cardiac output monitor and the Uscom BP+ suprasystolic central blood pressure monitor are premium cardiovascular devices with FDA, CE and TGA approval, and practice changing applications in hypertension, heart failure and sepsis. The new sales network will include a mix of current and new distributors, partnerships and licenses.”

Mr Haken has an Intensive Care Nursing background and attained an MBA from Imperial College in London in 2004. Mr Haken is a medical device sales specialist having spent the last 16 years selling devices in Europe for a number of global companies including GE Medical, Medtronic, Philips, Novartis, Welch Allyn, Pfizer, Drager and Laerdal.

Uscom Limited is an innovative developer and manufacturer of premium cardiovascular devices and has two practice leading technologies in the field of cardiovascular monitoring both with FDA, CE and TGA approval. The USCOM is a practice leading ultrasonic cardiac output monitor with proven application in sepsis, hypertension and heart failure. The BP+ is the premium supra systolic central blood pressure monitor for the identification and management of hypertension and heart failure. Central BP is the new standard of care for monitoring blood pressure, replacing simple arm measurement technologies by measuring the BP at the level of the heart; the Uscom BP+ is the most advanced central BP monitor.

Successful capital raising to support new sales and distribution initiatives

September 18th, 2013

Uscom Limited today announced the raising of $1.065m in a combined private placement to new and current sophisticated investors and exercise of options by staff. The funds will be directed to support current sales and marketing initiatives and new distribution partnerships. The issue was managed by brokers Lodge Partners.

Executive Chairman of Uscom, Rob Phillips said, “Uscom has two premium cardiovascular products and we are focused on getting a dominant position for these products in the global market. This will involve high quality sales and distribution partnerships of depth and breadth. These funds will support the transition to this sales and marketing strategy and provide for inventory replenishment and manufacturing to fill orders.

Uscom is an innovative developer and manufacturer of premium cardiovascular devices and has two practice leading technologies in the field of cardiovascular monitoring, both with regulatory approval. The USCOM is a practice leading ultrasonic cardiac output monitor with proven application in sepsis, hypertension and heart failure. The BP+ is the premium supra systolic Central Blood Pressure monitor for the identification and management of hypertension and heart failure. Central BP is the new standard of care for monitoring blood pressure replacing simple arm measurement technologies by measuring the BP at the level of the heart; the Uscom BP+ is the emerging central BP monitoring technology.

USCOM: New Paediatric Publications in Sepsis and Emergency Care

July 3rd, 2013

Uscom Limited today announced the publication of two new papers published in the field of paediatrics from four world leading centres in London and Canada on studies of USCOM in paediatric sepsis and paediatric emergency medicine.

The London study was a collaboration between authors from the paediatric intensive care units at Kings College Hospital, London, and the Great Ormond St Hospital for Children, London. The study was conducted over 36 months in the Kings College Hospital Intensive Care Unit and demonstrated that the serial use of USCOM to identify different haemodynamic patterns in paediatric sepsis improved clinical management of children. This study forms the foundation for a large scale, global multi-centre randomized controlled trial to establish new global practice management protocols for sepsis in children based on USCOM.

The Canadian study was a collaboration between authors from The University of Ottowa, Canada and McMasters University in Ontario, Canada. They evaluated the utility of USCOM in the demanding pediatric medical emergency team setting with the USCOM device operated by physicians and non physicians in acutely ill children. The study concluded that USCOM is applicable in this setting and could be used to identify therapeutic goals for more effective management of critically ill children.

Executive Chairman of Uscom, Rob Phillips said, “These world leading centres have been using USCOM in clinical practice for a number of years and progressively working to define it’s role as best practice in the management of children; this is the time consuming and thorough process of medical adoption. These studies provide further evidence that USCOM is being adopted as the gold standard cardiac monitor in paediatrics, particularly for best management of sepsis and septic shock in children.”

USCOM also has proven applications in management of adult sepsis and septic shock with recent publication of the Smith Madigan Inotropy Index and the BUSH protocol results in Australia demonstrating significant improvements in mortality and cost of management using USCOM guided haemoydnamic management.

References:

  1. Deep A, Goonasekera CDA, Wang Y, Brierley J. Evolution of haemodynamics and outcome of fluid refractory septic shick in children. Int Care Med 2013 DOI 10.1007/s00134-013-3003-z
  2. Zorko DJ, Choong K, Gilleland J, Agar B, Baker S, Brennan C, Pullenayegum E. Urgent Ultrasound Guided Hemodynamic Assessments by a Pediatric Medical Emergency Team: A Pilot Study. PLoS ONE 2013; 8(6): e66951. doi:10.1371/journal.pone.0066951
  3. CSU researchers enhance life-saving medical invention

Uscom Announces Italian Distribution Deal with Vega

June 25th, 2013

Uscom Limited today announced the completion of a distribution agreement with Vega S.p.A. to distribute USCOM products in Italy and nearby jurisdictions.

Vega S.p.A have specialized in the distribution of high technology medical devices since 1983. They provide Italian and regional distribution of precision medical instruments, equipment and machines, and devices for medical surgical and scientific applications principally in the hospital market and particularly in cardiology. Vega S.p.A also provide high level technical product support as part of their distribution commitment.

Executive Chairman of Uscom, Rob Phillips said, “We are delighted to welcome Vega S.p.A on board as part of our new drive to optimise global distribution. We now manufacture and market premium products into the cardiac output space, the USCOM line of products, and into blood pressure monitoring, the BP+ suprasystolic central blood pressure monitoring line of products, and are now developing reliable distribution of these technologies worldwide. We are currently negotiating a number of new relationships and seeking new worldwide partners to extend our distribution depth and reach.”

Uscom Limited manufacture accurate noninvasive devices for measurements of cardiac and vascular function. The USCOM 1A is an innovative and practice leading cardiac output monitor with application in Emergency Medicine, Critical Care Medicine, Paediatrics, and septic shock and fluid management. The Uscom BP+ is a unique and simple blood pressure monitoring device which uses suprasystolic oscillometry to measure blood pressure waves at the level of the heart. This central blood pressure measurement is considered more accurate than measurements of blood pressure in the arm and has application in the ICU, the ED, Paediatrics, military and retrieval applications, general ward, medical clinics, research applications and home blood pressure monitoring.

References:
Roman MJ, Devereaux RB, Kizer JR, Okin PM, Lee ET, Wang W, Umans JG, Calhoun D, Howard BV. High Central Pulse Pressure is Independently Associated With Adverse Cardiovascular Outcome. The Strong Heart Study. Journal of the American College of Cardiology 2009;15(18):1730-1734. Doi:10.1016/j.jacc.2009.05.070.
Roman MJ. Central blood pressure: A new vital sign? Artery Research 2009(3):125-127.

Uscom Completes Pulsecor Asset Purchase and Acquires New BP+ Central Blood Pressure Device

June 18th, 2013

Uscom Limited today announced completion of the purchase of all assets of Pulsecor Limited in exchange for 5m fully paid ordinary shares of Uscom Limited (UCM).

The Appendix 3B released to market values the issue price of the transaction at $0.50 AUD per UCM share. The acquired assets include the BP+ suprasystolic central blood pressure device, the CardioReporter pulse pressure wave analysis software, and 34 blood pressure measurement and analysis patents, and 4 trademarks.

Pulsecor Limited was valued at approximately $2.9million NZD at its last capital raising in May 2011 prior to regulatory approvals, and is Uscom’s first international corporate acquisition. Pulsecor’s BP+ product, currently being sold internationally, has US Food and Drug Administration (FDA) 510k, European CE mark and Australian Therapeutic Goods Administration (TGA) approval. Distribution of the BP+ device will be through Uscom’s growing global distribution network plus a network of new distribution partners.

The BP+ device uses patent protected “suprasystolic oscillometry” to measure simply and noninvasively central blood pressure at the heart, while older methods measure the pressure in the arm or hand. The unique BP+ measurements provide sensitive information about the health of the heart and vessels and are used to improve management of hypertension. These measurements are an improvement on conventional blood pressure measurements and can be applied in all research and clinical environments. Hypertension affects approximately 25% of all adults worldwide, and the hypertension market is thought to be in excess of $15billion US.

Professor Nigel Sharrock, a Professor of Anesthesiology at the Weill Cornell Medical College and anesthetist at The New York Hospital for Special Surgery, and inventor of the Pulsecor devices has now joined the Uscom medical advisory board as a specialist in cardiovascular medicine and anesthesia. Professor Sharrock believes that the combination of the USCOM and BP+ products can potentially change global hypertension practice.

Executive Chairman of Uscom, Rob Phillips said, “This is the holy grail of cardiovascular medicine; combining noninvasive cardiac output with central blood pressure to provide accurate measurements otherwise only available with invasive cardiac catheters, puts Uscom a long way ahead of current clinical practice. This acquisition changes the game for Uscom and has significantly grown the opportunity of the company. The combined Uscom and Pulsecor patent portfolio also creates a product pipeline well into the future.”

Combining accurate measurements of heart and vessel function using the Uscom products, USCOM 1A and the BP+, it is planned to create a new generation of noninvasive cardiovascular monitors. These devices will have application in the ICU, the ED, paediatrics, military and retrieval applications, general ward, medical clinics, research applications and home care, and improve management in hypertension, sepsis, heart failure and fluid management.

K&L Gates (Australia) and BDO have advised Uscom Limited in the transaction.

References:
Roman MJ, Devereaux RB, Kizer JR, Okin PM, Lee ET, Wang W, Umans JG, Calhoun D, Howard BV. High Central Pulse Pressure is Independently Associated With Adverse Cardiovascular Outcome. The Strong Heart Study. Journal of the American College of Cardiology 2009;15(18):1730-1734. Doi:10.1016/j.jacc.2009.05.070.
Roman MJ. Central blood pressure: A new vital sign? Artery Research 2009(3):125-127.

Uscom progress report - Pulsecor acquisition

June 14th, 2013

Uscom has released a progress report presentation on the Pulsecor acquisition and the BP+ central blood pressure device.

View the Presentation on the ASX

Uscom – the cardiovascular device company

Bringing together noninvasive and accurate central blood
flow and central blood pressure measurement has been
the holy grail of cardiovascular medicine. Uscom now has
the technology to do that.

Uscom to Acquire Pulsecor and New Blood Pressure Products

May 30th, 2013

Uscom Limited today signed a deed to acquire all assets of Pulsecor Limited. Pulsecor Limited is a New Zealand company which has developed novel non-invasive central blood pressure measurement methods pioneered at the Weill Cornell Medical College in New York. Under terms of the deed and on completion Uscom will acquire all Pulsecor technology, products and 34 global patents and patent applications related to measurement and monitoring of blood pressure in exchange for 5 million fully paid ordinary Uscom shares.

Pulsecor was valued at approximately $2.9million NZD at its last capital raising in May 2011 and is Uscom’s first international corporate acquisition. Pulsecor’s BP Plus product, currently being sold internationally, has US Food and Drug Administration 510k, European CE mark and Australian Therapeutic Goods Administration approval. The BP Plus device will be sold through Uscom’s growing global distribution network.

The BP Plus device provides unique information about the heart and vessels which can be used to detect early cardiovascular disease and improve management of hypertension. Hypertension affects approximately 25% of all adults worldwide, while the hypertension market is thought to be in excess of $15billion US. BP Plus is an improvement on current blood pressure measurement methods and can be used in all research and clinical environments including the ICU, operating theatre, medical clinics and for in home use. Current methods measure blood pressure in the arm or hand, while the BP Plus measures central blood pressure at the heart simply and noninvasively.

Professor Nigel Sharrock, an anesthetist at The New York Hospital for Special Surgery, a Professor of Anesthesiology at the Weill Cornell Medical College, and inventor of the Pulsecor devices said “This is a great step forward for Uscom and will ensure that Pulsecor products have the maximum clinical and commercial impact. We have spent 10 years developing Pulsecor and we believe these products are poised to change global hypertension practice. There is a fine scientific and cultural fit between Uscom and Pulsecor; both companies have world leading devices meeting urgently required clinical needs in growing global markets. I look forward to working with Uscom to further develop a truly major medical device company specializing in noninvasive cardiovascular monitoring.” Professor Sharrock will join the Uscom Medical Advisory Board as a specialist in cardiovascular medicine and anesthesia on completion of the transaction.

Executive Chairman of Uscom, Rob Phillips said, “We anticipate scientific, commercial and strategic synergies from this acquisition. We believe this acquisition will change the cardiovascular medical device market and is anticipated to provide immediate access to revenue for Uscom as we feed the BP Plus into our developing global distribution channels.”

The Pulsecor BP Plus device now sits beside the USCOM, as patent protected, innovative products for measurement of cardiac and vascular function. Together they provide noninvasive measurements previously only available with intra cardiac catheters and are conceived to create a new generation of noninvasive cardiovascular monitors for specialized care in hypertension, sepsis, heart failure and fluid management.

The deed is conditional on completion of satisfactory due diligence by Uscom. K&L Gates (Australia) and BDO have advised Uscom Limited in the transaction.

References:
www.pulsecor.com

Roman MJ, Devereaux RB, Kizer JR, Okin PM, Lee ET, Wang W, Umans JG, Calhoun D, Howard BV. High Central Pulse Pressure is Independently Associated With Adverse Cardiovascular Outcome. The Strong Heart Study. Journal of the American College of Cardiology 2009;15(18):1730-1734. Doi:10.1016/j.jacc.2009.05.070.
Roman MJ. Central blood pressure: A new vital sign? Artery Research 2009(3):125-127.

New USCOM Method for Measurement of Heart Function

May 8th, 2013

Uscom Limited today announced the publication of a new method for measurement of cardiovascular performance based on USCOM. The derivation and validation of the method was published in the British Journal of Anaesthesia by Professor Brendan Smith and Veronica Madigan. The publication represents 6 years of pure and clinical research between the authors.

The new parameter, the Smith Madigan Inotropy Index, is based on the unique measures of USCOM and provides a simple and improved method for identifying and treating all cardiovascular conditions including heart failure, hypertension and sepsis. Measurement of the Smith Madigan Inotropy Index can be performed in less than 2 minutes using the non-invasive USCOM, and replaces complex catheter based measurements that are invasive, time consuming, costly and are associated with the clinical risk of complications.

Professor Smith works for the NSW Department of Health as a consultant Anaesthetist and Intensivist and is a Professor with the School of Biomedical Sciences at the Charles Sturt University, Bathurst. His special interest is the management of sepsis and septic shock.

Professor Smith said, “USCOM has been a central part of my clinical practice for over eight years and the Inotropy Index has developed from this practice. The Inotropy Index is an improvement on other measures of cardiovascular function and will allow for greater application of the USCOM in clinical practice. Our team is currently working on incorporating these parameters into new clinical treatment algorithms to simplify and improve care of sepsis, heart failure, major surgery, circulatory disorders and hypertension. In our hospital the Inotropy Index is saving lives in these complex diseases and is a major component of the BUSH protocol for treatment of sepsis and septic shock.”

Executive Chairman of Uscom Limited, Rob Phillips said, “Professor Smith and Veronica Madigan are early adopters of USCOM and world leaders in the field of clinical haemodynamics. The Inotropy Index will change the way we look at cardiovascular function and is already saving lives and changing the management of sepsis and septic shock. Not only is the Inotropy Index a better measure of cardiovascular function, it can be acquired non-invasively in under 2 minutes.”

The Smith Madigan Inotropy Index is a key measure in the BUSH protocol for treatment of sepsis and septic shock. A study presented at the Society of Critical Care Medicine in January by Professor Smith demonstrated that adoption of the BUSH Protocol Australia wide between 2006-2012 would have saved 8,237 lives. The Smith Madigan Inotropy Index is an USCOM patent protected measure and will be released as a new feature on USCOM devices following this publication.

References:
Smith BE, Madigan VM, Non-invasive method for rapid bedside estimation of inotropy: Theory and preliminary clinical validation. British Journal of Anaesthesia 2013, DOI 10.1093/BJA/AET118
Smith BE, Phillips RA, Madigan V, West MJ. Decreased Mortality, Morbidity and Emergency Transport in Septic Shock; A New Protocol Based on Advanced Noninvasive Haemodynamics (USCOM) and Early Antibiotics. Crit Care Med 2012; 40(12):1023. doi: 10.1097/01.ccm.0000424114.76434.7a

USCOM Strategic Focus: New Distribution in Mexico

May 1st, 2013

Uscom Ltd today announced the appointment of Grupo SIM as regional distributor for Uscom Ltd products in Mexico. The Grupo SIM specialized subsidiary distributes medical products into intensive care, pulmonary and respiratory care, diagnostic cardiology, cardiac monitoring, critical care and neonatal and paediatric critical care units in Mexico.

Mexico has a population of 115m and the Mexican medical device market was estimated to be $3.4b US in 2012. This market is supported by a rapid population growth, increasing health expenditure, a high incidence of chronic diseases, and a commitment to acquisition of new technology in the public health sector. The improved economic outlook for the 2013 – 2017 period has further boosted growth prospects.

The appointment is part of the execution of the third leg of the strategic restructure of Uscom articulated at last year’s AGM by the Uscom Board to develop and expand global product distribution following capital raising and operational consolidation. Sales and distribution are the critical next steps for Uscom commercialisation.

Executive Chairman of Uscom, Rob Phillips said, “Distribution is the final piece in the commercialisation puzzle. We have validated and approved technology, established world leading and practice changing science, and our mission now is to establish an effective and penetrating network of distribution to deliver our products to market. Mexico is a huge and growing market, and Grupo SIM an excellent company. We are looking forward to working closely with Grupo SIM to realise the Mexican sales opportunity. We are intent on establishing an effective global network of distribution to provide the sales foundation on which to build a multi-product company of high profitability.”

References:
www.gruposim.com
www.espicom.com/mexico-medical-device-market

New Paper Confirms a Large Reduction in Sepsis Deaths and Hospital Costs Using USCOM

January 22nd, 2013

Non-invasive cardiac monitoring company Uscom Limited today announced the international presentation of independent data that confirms significant life-saving and cost reduction associated with USCOM guided treatment of sepsis and septic shock.

The study of a six year Australian national ICU practice audit database by Professor Brendan Smith of Charles Sturt University was published in the latest edition of the international journal Critical Care Medicine and presented at the Society of Critical Care Medicine Annual meeting in Puerto Rico. The Society of Critical Care Medicine is the largest multi-professional organization dedicated to ensuring excellence and consistency in the practice of critical care. The Society represents over 16,000 members in over 100 countries.

The study found that the Bathurst USCOM Hemodynamic (BUSH) protocol reduced mortality by 94% and management costs by 45% over the 6 year study period. The study concluded that if the BUSH protocol results were duplicated Australia wide the savings would have been 8,237 lives and $1.01bn.

Professor Smith said, “These results demonstrate a potential new gold standard for the management of sepsis and we are now looking to share our experience and improve care in Australia and worldwide.”

Data from septic shock patients treated Australia-wide and in Bathurst between 2007 to 2012 were extracted from the Australian and New Zealand Intensive Care Society (ANZICS) Centre for Outcomes and Resource Evaluation (CORE) database was analysed for trends in mortality, morbidity, emergency transport costs and cost of hospital stay. The database was established to benchmark clinical standards of practice.

Septic shock, also known as blood poisoning, is a complex medical condition with a patient mortality of 22 to 76 per cent. It is characterized by extreme and variable cardiovascular dysfunction which results in a critical oxygen shortage to the cells and leading ultimately to death. The disease has been increasing in Australia at a rate of 10% per annum for the last 6 years while cancer and heart disease mortality have been falling. Sepsis has been declared a global medical emergency by the Global Sepsis Alliance.

Professor Smith said “The Bathurst USCOM Hemodynamic (BUSH) protocol, was introduced at Bathurst Base Hospital, a rural hospital in Australia, in 2007. The protocol is based on a multidisciplinary approach, immediate diagnosis, rapid administration of antibiotics and personalised cardiovascular resuscitation directed by advanced non-invasive USCOM hemodynamics. Each year we see tragic cases of septicemia unnecessarily claiming Australian lives. Widespread adoption of the BUSH protocol could significantly reduce this risk and save health care costs.”

Professor Smith said, “Since the Bathurst introduction of the BUSH protocol, most sepsis patients were treated in less than 60 minutes, and mortality has fallen to approximately 5.6% per year in those patients treated according to the BUSH protocol. Renal failure was reduced from 74 per cent to 14 per cent, and emergency transport to tertiary referral centres was reduced by 87 per cent, while other hospital costs were reduced by 45%.”

Uscom Chief Executive Officer Rob Phillips said, “We welcome this independent outcomes evidence that demonstrates USCOM is significantly contributing to making sepsis a curable disease. This study demonstrates the contribution USCOM can make to global health economics and provides the clinical and health economic evidence necessary for large national and international health management organizations to adopt the USCOM technology.

“We are committed to creating shareholder value by demonstrating the significant advantages of our world-leading patented Australian platform medical device technology to a range of potential international strategic partners. The cost benefits demonstrated in this study define the commercial opportunities that can be developed in these partnerships.” Mr Phillips said.

The USCOM device has proven applications in paediatrics, emergency and intensive care medicine and anesthesia. It is the clinical gold standard device for management of adult and paediatric sepsis, and for the guidance of fluid therapy, and in heart failure and hypertension.

References:
Smith BE, Phillips RA, Madigan V, West MJ. Decreased Mortality, Morbidity and Emergency Transport in Septic Shock; A New Protocol Based on Advanced Noinvasive Haemodynamics and Early Antibiotics. Crit Care Med 2012; 40(12):1–328. doi: 10.1097/01.ccm.0000424114.76434.7a